Genmab pushes rina-S into its third phase 3 (ApexOnco OncologyPipeline) - Nov 13, 2025 - "After months of anticipation Genmab is ready to launch the Rainfol-04 trial, its third phase 3 study of rinatabart sesutecan, the anti-folate receptor alpha (FRα) ADC originated by ProfoundBio. The start, however, will come slightly later than originally projected by the company...According to a new clinicatrials.gov listing the study is now expected to begin in January 2026, instead of the second half of 2025. It will evaluate rina-S as second-line maintenance therapy in platinum-sensitive ovarian cancer patients with HRD mutations, including BRCA, and the asset will be tested with or without Avastin, versus Avastin or observation, which represents the standard of care in this indication. PFS is the primary endpoint."
Platinum sensitive • Trial status • Ovarian Cancer
|